Analysts Estimate Report : What to Look Out for PLx Pharma (NASDAQ:PLXP)

0
145

Earnings results for PLx Pharma (NASDAQ:PLXP)

PLx Pharma Inc. is expected* to report earnings on 03/12/2021 before market open. The report will be for the fiscal Quarter ending Dec 2020. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.29. The reported EPS for the same quarter last year was $-0.45.

Analyst Opinion on PLx Pharma (NASDAQ:PLXP)

2 Wall Street analysts have issued ratings and price targets for PLx Pharma in the last 12 months. Their average twelve-month price target is $12.00, predicting that the stock has a possible upside of 53.26%. The high price target for PLXP is $12.00 and the low price target for PLXP is $12.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of “Buy.”

PLx Pharma has received a consensus rating of Buy. The company’s average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings. According to analysts’ consensus price target of $12.00, PLx Pharma has a forecasted upside of 53.3% from its current price of $7.83. PLx Pharma has only been the subject of 1 research reports in the past 90 days.

Dividend Strength: PLx Pharma (NASDAQ:PLXP)

PLx Pharma does not currently pay a dividend. PLx Pharma does not have a long track record of dividend growth.

Insiders buying/selling: PLx Pharma (NASDAQ:PLXP)

In the past three months, Evelo Biosciences insiders have bought more of their company’s stock than they have sold. Specifically, they have bought $2,001,282.00 in company stock and sold $0.00 in company stock. Only 7.30% of the stock of Evelo Biosciences is held by insiders. 84.57% of the stock of Evelo Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Earnings and Valuation of PLx Pharma (NASDAQ:PLXP

Earnings for Evelo Biosciences are expected to grow in the coming year, from ($2.23) to ($1.77) per share. The P/E ratio of Evelo Biosciences is -3.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Evelo Biosciences is -3.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Evelo Biosciences has a P/B Ratio of 5.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here